Contact Us
Subscribe
e-Edition

Dashboard
Logout

- My Account
- Dashboard
- Profile
- Saved items
- Logout

Site search

63° Cloudy
- Malvern, AR (72104)
  Today
  
  Generally cloudy. Slight chance of a rain shower. High 74F. Winds SE at 5 to 10 mph..
  
  Tonight
  
  Cloudy skies. A stray shower or thunderstorm is possible. Low near 65F. Winds S at 5 to 10 mph.
  
  Updated: November 17, 2025 @ 10:12 am
- Full Forecast

Home
- Contact Us
- Subscribe
News
- Local News
Sports
Obituaries
Photos
- Photo Galleries
- Videos
e-Edition
Classifieds
- Place an ad
Archives
Readers Choice 2025
Breast Cancer Quiz

Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Merck & Co (NY:MRK)

93.82 +0.90 (+0.97%)

Streaming Delayed Price Updated: 11:19 AM EST, Nov 17, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Merck & Co

< Previous 1 2

...

20 21 22 23 24 25 26 27 28

...

99 100 Next >

Merck's Gardasil Vaccine Slowdown In China Bites Again, Stock Falls On Weak 2025 Outlook ↗

February 04, 2025

Merck posted Q4 sales of $15.62 billion, driven by Keytruda's 19% growth. FY25 guidance lags estimates, citing Gardasil shipment pause in China and forex impact.

Via Benzinga

PayPal, Estée Lauder, UBS And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session ↗

February 04, 2025

Via Benzinga

Merck’s (NYSE:MRK) Q4 Sales Top Estimates But Stock Drops

February 04, 2025

Global pharmaceutical company Merck (NYSE:MRK) reported Q4 CY2024 results beating Wall Street’s revenue expectations, with sales up 6.8% year on year to $15.62 billion. On the other hand, the company’s...

Via StockStory

Merck Tops Q4 Forecasts, But Dow Jones Giant Dives On 2025 Guidance ↗

February 04, 2025

Merck topped Wall Street's Q4 expectations Tuesday, but the stock is taking a hit on light guidance.

Via Investor's Business Daily

Topics Stocks

Merck Announces Fourth-Quarter and Full-Year 2024 Financial Results

February 04, 2025

From Merck & Co., Inc.

Via Business Wire

Market Whales and Their Recent Bets on MRK Options ↗

January 31, 2025

Via Benzinga

A Closer Look at Merck & Co's Options Market Dynamics ↗

January 29, 2025

Via Benzinga

Earnings Scheduled For February 4, 2025 ↗

February 04, 2025

Via Benzinga

Merck Vs. Pfizer: Which Pharmaceutical Giant Will Prevail In Q4 Earnings? ↗

February 03, 2025

Merck and Pfizer are heading into fourth quarter earnings with different technical setups, leaving investors unsure of which stock will prevail. While Merck shows short-term strength, Pfizer is...

Via Benzinga

The Dogs Of The Dow 2025 ↗

January 31, 2025

The Dogs of the Dow is an investing strategy well-known to retail and institutional investors.

Via Talk Markets

Topics Stocks Stocks / Equities

Is Big Pharma About To Win? Goldman Sachs Weighs In On 340B And Medicaid Shifts ↗

January 31, 2025

Goldman Sachs analyst Salveen Richter highlights potential benefits for biopharma from 340B reforms, while Medicaid cuts could pose risks for companies with significant drug exposure.

Via Benzinga

5 Top Stocks to Buy in February 2025 ↗

January 31, 2025

All of them have great upside.

Via The Motley Fool

Merck Receives Positive EU CHMP Opinion for CAPVAXIVE™ (Pneumococcal 21-valent Conjugate Vaccine) for Pneumococcal Vaccination in Adults

January 31, 2025

From Merck & Co., Inc.

Via Business Wire

Forecasting The Future: 12 Analyst Projections For Merck & Co ↗

January 28, 2025

Via Benzinga

Balancing Dividends and Fundamentals: The Case of NYSE:MRK. ↗

January 28, 2025

Exploring MERCK & CO. INC. (NYSE:MRK)'s dividend characteristics.

Via Chartmill

Merck Announces Decision to Stop Phase 3 HYPERION Trial Evaluating WINREVAIR™ (sotatercept-csrk) Early and Move to Final Analysis

January 30, 2025

From Merck & Co., Inc.

Via Business Wire

RFK Jr. And Big Pharma: Health Secretary Hopeful Answers Pointed Questions On Drugs, Insurance, Trump Exec Orders ↗

January 29, 2025

Kennedy seeks to be Secretary of Health and Human Services — a position that would put him in charge of the health of the American people.

Via Benzinga

Topics Government

The RFK Jr. Effect: Biotech Stocks Brace For 'Games' In Senate Hearings ↗

January 29, 2025

The Senate will meet Wednesday to start the confirmation hearing process for Robert F. Kennedy Jr.

Via Investor's Business Daily

Why This Beaten-Down Stock Is a Buy in 2025 and Beyond ↗

January 27, 2025

Via The Motley Fool

NYSE:MRK is probably undervalued for the fundamentals it is displaying. ↗

January 23, 2025

MERCK & CO. INC. (NYSE:MRK) is an undervalued gem with solid fundamentals.

Via Chartmill

Merck Announces Second-Quarter 2025 Dividend and $10 Billion Share Repurchase Authorization

January 28, 2025

From Merck & Co., Inc.

Via Business Wire

FDA Grants Priority Review to Merck’s Application for WELIREG® (belzutifan) for the Treatment of Patients With Advanced Pheochromocytoma and Paraganglioma (PPGL)

January 27, 2025

From Merck & Co., Inc.

Via Business Wire

These Were the 5 Worst-Performing Stocks in the Dow Jones Industrial Average in 2024 ↗

January 25, 2025

Via The Motley Fool

Topics Stocks

Merck/Eisai's Keytruda Plus Lenvima Regime Shows Mixed Data In Esophagus Cancer Study ↗

January 24, 2025

Merck and Eisai report mixed results from LEAP-015 trial of Keytruda and Lenvima in HER2-negative gastroesophageal cancer treatment.

Via Benzinga

Moderna Yo-Yos After European Officials Ink Supply Deal For Covid Shots ↗

January 24, 2025

Moderna won an agreement for its Covid vaccines in Europe on Friday, but Moderna stock reversed its early gains.

Via Investor's Business Daily

Merck and Eisai Provide Update on Phase 3 LEAP-015 Trial Evaluating KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) in Combination with Chemotherapy in Patients with Certain Types of Gastroesophageal Adenocarcinoma

January 24, 2025

From Merck & Co., Inc.

Via Business Wire

RJK Jr.'s Involvement In Merck Lawsuit Faces Scrutiny Ahead Of Senate Hearing ↗

January 23, 2025

Robert F. Kennedy Jr., HHS secretary nominee, faces criticism for financial ties to vaccine lawsuits, raising ethical concerns over regulatory impartiality.

Via Benzinga

Topics Lawsuit

3 Unstoppable Stocks to Buy That Wall Street Thinks Will Soar More Than 35% ↗

January 23, 2025

Via The Motley Fool

Analyst Praises AMD-Partner Absci's Practical Approach, Sees 118% Stock Upside ↗

January 22, 2025

Needham initiated a Buy rating for Absci (ABSI), noting its AI-powered drug discovery platforms, strategic partnerships, and $9 price target.

Via Benzinga

Moderna Surges After Larry Ellison Calls Out The Potential Of AI In Cancer Vaccines ↗

January 22, 2025

Ellison, Oracle's chairman, pointed to the use of AI to develop drugs like Moderna's cancer vaccine.

Via Investor's Business Daily

Topics Artificial Intelligence

< Previous 1 2

...

20 21 22 23 24 25 26 27 28

...

99 100 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Sections

News
Sports
Business
Local Events
Entertainment
Obituaries
Photos
Online Features

Services

Subscription Services
Submission Forms
Promote Your Event
Classifieds
Place an Ad
Email Alerts
Search
Weather

Malvern Daily Record

malvern-online.com
219 Locust Street
Malvern, AR 72104
Phone: 501-337-7523
Email: advertising@malvern-online.com

Facebook

Browser Compatibility

Your browser is out of date and potentially vulnerable to security risks.
We recommend switching to one of the following browsers:

Microsoft Edge Google Chrome Firefox

Malvern, AR (72104)

Today

Tonight

Merck & Co (NY:MRK)

All News about Merck & Co

Sections

Services

Malvern Daily Record